How shall we treat locally advanced triple negative breast cancer? [version 2; peer review: 2 approved]
Triple negative breast cancer (TNBC) has been shown to respond to neoadjuvant chemotherapy (NACT). It has been established that achieving pathological complete response (pCR) for certain aggressive subtypes of breast cancer, including HER-2 (over-expressed) and TNBC, provides an important surrogate...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
F1000 Research Ltd
2020-05-01
|
| Series: | F1000Research |
| Online Access: | https://f1000research.com/articles/8-1649/v2 |